title: Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.
abstract: DC Bead is a drug delivery embolisation system that can be loaded with doxorubicin or irinotecan for the treatment of a variety of liver cancers. In this study we demonstrate that the topoisomerase I inhibitor topotecan hydrochloride can be successfully loaded into the DC Bead sulfonate-modified polyvinyl alcohol hydrogel matrix, resulting in a sustained-release drug eluting bead (DEBTOP) useful for therapeutic purposes. The in vitro drug loading capacity, elution characteristics and the effects on mechanical properties of the beads are described with reference to our previous work with irinotecan hydrochloride (DEBIRI). Results showed that drug loading was faster when the solution was agitated compared to static loading and a maximum loading of ca. 40-45 mg topotecan in 1 ml hydrated beads was achievable. Loading the drug into the beads altered the size, compressibility moduli and colour of the bead. Elution was shown to be reliant on the presence of ions to perform the necessary exchange with the electrostatically bound topotecan molecules. Topotecan was shown by MTS assay to have an IC(50) for human pancreatic adenocarcinoma cells (PSN-1) of 0.22 and 0.27 microM compared to 28.1 and 19.2 microM for irinotecan at 48 and 72 h, respectively. The cytotoxic efficacy of DEBTOP on PSN-1 was compared to DEBIRI. DEPTOP loaded at 6 & 30 mg ml(-1), like its free drug form, was shown to be more potent than DEBIRI of comparable doses at 24, 48 & 72 h using a slightly modified MTS assay. Using a PSN-1 mouse xenograft model, DEBIRI doses of 3.3-6.6 mg were shown to be well-tolerated (even with repeat administration) and effective in reducing the tumour size. DEBTOP however, was lethal after 6 days at doses of 0.83-1.2 mg but demonstrated reasonable efficacy and tolerability (again with repeat injection possible) at 0.2-0.4 mg doses. Care must therefore be taken when selecting the dose of topotecan to be loaded into DC Bead given its greater potency and potential toxicity.
authors.affiliation: Biocompatibles UK Ltd., Farnham Business Park, Weydon Lane, Farnham, Surrey, GU9 8QL, UK.
authors.forename: Richard E J
authors.initials: RE
authors.lastname: Forster
authors.forename: Sharon A
authors.initials: SA
authors.lastname: Small
authors.forename: Yiqing
authors.initials: Y
authors.lastname: Tang
authors.forename: Clare L
authors.initials: CL
authors.lastname: Heaysman
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Lloyd
authors.forename: Wendy
authors.initials: W
authors.lastname: Macfarlane
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Phillips
authors.forename: Milan D
authors.initials: MD
authors.lastname: Antonijevic
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Lewis
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D045744:Cell Line, Tumor; D006801:Humans; D000077146:Irinotecan; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D019772:Topotecan / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D000077146:Irinotecan; D019772:Topotecan; D002166:Camptothecin